Moderna mRNA flu vaccine to get FDA panel review
Moderna’s experimental mRNA flu shot will be reviewed by a Food and Drug Administration (FDA) advisory panel next month, a move that suggests a more stable approach to drug reviews after the firing of former agency head Marty Makary. The panel will meet June 18 to discuss and mak.

Expanded Context
Brimstone Report is tracking this as a curated border & immigration brief. The source report from The Hill says: Moderna’s experimental mRNA flu shot will be reviewed by a Food and Drug Administration (FDA) advisory panel next month, a move that suggests a more stable approach to drug reviews after the firing of former agency head Marty Makary. The panel will meet June 18 to discuss and mak.
This page is not original reporting. It gives readers the Brimstone view of the story: what is known from the attributed source, why the topic matters, and where to continue reading the original report.
At publication, this brief is anchored to a single attributed source. Readers should treat early details as provisional until additional reporting, official statements, or documents appear.
Why It Matters
Border and immigration stories connect law enforcement, federal policy, local services, courts, and humanitarian concerns. Context helps explain which part of the system is involved.
Key Facts
- Primary source: The Hill
- Published: May 21, 2026, 9:53 PM UTC
- Coverage area: Border & Immigration
- Brimstone role: curated summary, explanation, and source attribution
- Topic signals: developing story metadata
Timeline
- Source published: May 21, 2026, 9:53 PM UTC
- Brimstone indexed: Added to the curated Brimstone feed and linked to related coverage.
- Next update to watch: Additional sourcing, official confirmation, court or agency records, or follow-up reporting.
Source Attribution
This Brimstone page summarizes and contextualizes a third-party report. Continue to the original publisher for full reporting, documents, quotes, and updates.
Read Original Source